In our previous study, we reported a rate of 48.3% HER2-low tumors, which was within the range of approximately half of HER2-negative breast cancer patients (31.0% to 60.6%) reported by Prat and coworkers in a recent review article [20,58]. This evidence concerns the gene ERBB2 and breast cancer.